A multicenter randomized clinical trial conducted by Smith et al. [54] revealed that inhibition of IGF-IR with teprotumumab was more effective than placebo in patients with moderate to severe TAO in improving CAS and proptosis, including improvements in double vision. The gene discussed is IGF1R; the disease is thromboangiitis obliterans.